Navigation Links
Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today that the Company intends to initiate a Phase 1b clinical trial to demonstrate the efficacy and safety of the improved formulation of its transdermal insulin product, TPM-02/Insulin, containing long-acting insulin. The trial is expected to commence in the second quarter of 2007.

TPM-02/Insulin gel is being developed as a novel "needle-free" way of administering insulin to patients with diabetes. Following the successful completion of a Phase 1a study utilizing short-acting insulin, this trial will assess an optimized formulation of long-acting insulin. Recent advancements in Phosphagenics' patented TPM-02 delivery system have enabled the formulation of long-acting insulin; which is significantly less expensive than short- acting insulin, provides appropriate levels of insulin in humans and is commercially attractive.

"In August of 2006, our Phase 1a study demonstrated that a single application of TPM-02/Insulin gel rapidly delivered insulin across the skin and into the bloodstream without any adverse reactions," said Dr. Esra Ogru, Executive Vice President at Phosphagenics. "Additionally, it significantly lowered blood glucose, insulin and c-peptide levels."

"The Phase 1b study is intended to provide additional supporting data for an Investigational New Drug application to the U.S. Food and Drug Administration," continued Dr. Ogru. "The trial will be conducted by CMAX at the Royal Adelaide Hospital, South Australia, will include up to 45 healthy volunteers and is expected to lead directly into the start of a large multi- site Phase 2 trial that is likely to include up to several hundred patients."

"This is an important step for the development and commercialization of TPM-02/Insulin," said Harry Rosen, President and CEO of Phosphagenics. "This technology has the potential to p
'"/>




Page: 1 2

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/30/2015)... Flexpoint Ford, a private equity firm focused on the ... has entered into a partnership with Alan MacKenzie ... Therapeutics, LLC (Kastle).  The new company, headquartered in ... and commercializing pharmaceuticals targeted toward diseases with high unmet ... approved for marketing, as well as clinical assets in ...
(Date:7/30/2015)... DUBLIN, Ohio, July 30, 2015  Cardinal Health ... $27.5 billion, an increase of 20 percent, and ... operations of $1.00, an increase of 20 percent. ... million. On a GAAP basis, operating earnings increased ... from continuing operations increased 29 percent to $0.88. ...
(Date:7/30/2015)... HeartWare International, Inc . (NASDAQ: HTWR ), ... support technologies that are revolutionizing the treatment of ... $73.6 million for the quarter ended June 30, ... ended June 30, 2014.  Currency fluctuations impacted revenue ... points, during the three months ended June 30, ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 34
... Nov. 1 Obesity is common in,children with ... of a,shortened life expectancy., More than 25 ... are overweight or obese, say researchers from The ... a study,released in the current issue of Pediatrics. ...
... 1 A new study lead by James ... Pennsylvania School of,Medicine and presented by Charles Simone ... concluded that when it comes to seeking,information on ... differ from English-speaking patients with regards to,both frequency ...
Cached Medicine Technology:Obesity Common in Children with Heart Disease 2Obesity Common in Children with Heart Disease 3University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites 2University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites 3
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the ... Chewable as a simple way to get the natural ingredients that may help ...
(Date:7/30/2015)... WASHINGTON (PRWEB) , ... July 30, 2015 , ... ... the scientific program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on ... more than 300 cutting-edge health care technology vendors, will take place May 14-17, ...
(Date:7/30/2015)... County, CA (PRWEB) , ... July 30, 2015 ... ... home health care throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today ... as the new Palliative Care Administrator. Dr. Demoratz is a strong proponent of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... and fourth annual Institute Scholar Program. In partnership with Patient Experience Institute, these ... experience, develop leaders on the front lines and throughout the experience movement, and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied ... Mesothelioma Patient Registry Act of 2015’. The bill was introduced in Congress yesterday ... (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
... cartilage could lead to earlier detection of Osteoarthritis. An ... Osteoarthritis, a painful disease //where the cartilage between the ... the cartilage direct it only shows that the gap ... at the University of Texas, have been developing a ...
... to a study from researchers, steadfast and simple blood ... readily detects diabetes in the doctor's surgery.// Around three ... themselves at increased risk of heart disease and kidney ... requires many hours of prior fasting. However, doctors at ...
... Medicine have recently found that the brain's 'nose plug' that ... smelling something, even though the odour is still there.// ... Science show that a protein called CNGA4 helps plug the ... is to detect smells and send that information to the ...
... implanted near the eye’s retina is well on its ... eye diseases such as Retinitis Pigmentosa and age-related degeneration ... development.// , The implant works for eye diseases in ... use of the eye’s photoreceptors. These receptors convert images ...
... Among people with low-calcium diets, even a modest increase in ... of colon cancer. Researchers evaluated the diet and colon cancer ... surveys.// They found that those who consumed 800 to 900 ... left-side colon cancer by 50 to 60 percent. ,The ...
... According to researchers, people with receding lower jaws are more ... condition which is characterised by collapse of the tissues// at ... flow of air into and out of the lungs. Often, ... breathing many times in the night. Lack of oxygen to ...
Cached Medicine News:
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Manufactured in titanium....
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: